

Part II **Organizational Action** (continued)

17 List the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is based ▶
See attachment to Form 8937, Part II - Quanterix Corporation

18 Can any resulting loss be recognized? ▶ See attachment to Form 8937, Part II - Quanterix Corporation

19 Provide any other information necessary to implement the adjustment, such as the reportable tax year ▶
See attachment to Form 8937, Part II - Quanterix Corporation

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

Sign Here
Signature ▶ *Vandana Sriram* Date ▶ 9/4/2025

Paid Preparer Use Only	Print your name ▶ Vandana Sriram	Preparer's signature	Date	Check <input type="checkbox"/> if self-employed	PTIN
	Print/Type preparer's name			Firm's EIN ▶	
	Firm's name ▶			Phone no.	
	Firm's address ▶				

Quanterix Corporation
Attachment to Form 8937, Part II
Report of Organizational Actions Affecting the Basis of Securities

Disclaimer: The information in Form 8937 and this attachment does not constitute tax advice and does not purport to take into account the specific circumstances that may apply to particular categories of shareholders. The information set forth below reflects our expectations as to certain U.S. federal income tax consequences of the transactions below. No assurances can be given that the U.S. Internal Revenue Service will not disagree with or challenge the expected treatment of the transactions and the resulting consequences described herein. Each shareholder is urged to consult his, her, or its own tax advisor regarding the consequences of the transactions described herein, including the impact on tax basis resulting therefrom, any tax return reporting requirements, and the applicability and effect of U.S. federal, state, local, and foreign income and other tax laws in light of their own circumstances.

Part II, Question 14

On July 8, 2025 (“Merger Date”), Quanterix Corporation (“Quanterix”), Akoya Biosciences, Inc. (“Akoya”), and Wellfleet Merger Sub, Inc. (“Merger Sub”) effectuated a merger whereby Merger Sub (a wholly-owned subsidiary of Quanterix) merged with and into Akoya with Akoya continuing as the surviving corporation and becoming a wholly owned subsidiary of Quanterix (such transaction the “Merger”).¹ In connection with the Merger, each shareholder who held common stock of Akoya on Merger Date received (i) 0.1470 shares of common stock of Quanterix and (ii) \$0.37 in exchange for each share of Akoya of common stock owned.

No fractional shares of Quanterix were issued in the Merger. In lieu thereof, any holder of Akoya common stock who would otherwise have been entitled to receive fractional shares of Quanterix common stock was paid an amount in cash (rounded to the nearest whole cent and without interest and subject to any tax withholding) based on the volume weighted average trading value of Quanterix stock pursuant to the formula set forth in the Merger Agreement.

¹ The Merger was effectuated pursuant to the Amended and Restated Agreement and Plan of Merger date April 28, 2025 (the “Merger Agreement”).

Part II, Question 15

For each share of Akoya common stock exchanged, a U.S. shareholder will recognize gain equal to the excess of (i) the sum of the fair market value of Quanterix common stock received plus the cash received (including cash in lieu of fractional shares of Quanterix common stock) over (ii) the shareholder's adjusted tax basis in the Akoya common stock surrendered. A U.S. shareholder will recognize loss equal to the excess of (i) the shareholder's adjusted tax basis in the Akoya common stock surrendered over (ii) the sum of the fair market value of Quanterix common stock received plus the cash received (including cash in lieu of fractional shares of Quanterix common stock).

The initial tax basis of the Quanterix common stock received will be equal to its fair market value on the Merger Date.

Recipients receiving Quanterix common stock and cash in respect of "in-the-money" options to receive stock in Akoya should consult with their tax advisor to determine the U.S. tax and basis consequences arising from the receipt of such Quanterix common stock and cash. Similarly, recipients receiving Quanterix common stock and cash (or entitlements to such stock and cash) in respect of restricted and/or unvested common stock of Akoya are similarly urged to consult with their tax advisor.

Part II, Question 16

The tax basis of Quanterix common stock received by each Akoya shareholder will be equal to the fair market value of the Quanterix stock on Merger Date. [Based upon the volume-weighted average price of the Quanterix common stock as measured over the five-day trading period ending on the Merger Date], the fair market value of the Quanterix common stock has been determined to be [\$6.65910]. Other valuation methodologies may exist, and shareholders are urged to consult their tax advisors regarding these allocation calculations.

As an illustration, if an Akoya shareholder surrenders 100 shares of Akoya common stock, the shareholder will receive [14.7] shares of Quanterix common stock and [\$37] in cash. The total amount realized for each share of Akoya on July 8, 2025 is the sum of (i) approximately [\$.98 (.1470 * \$6.65910)] and (ii) [\$.37] in cash or approximately [\$1.35], which will be used (relative to such shareholders per share adjusted tax basis) to compute the gain or loss recognized with respect to each share of Akoya stock. Based upon the

illustrative computation, each Akoya shareholder will hold each whole share of Quanterix common stock received with an adjusted tax basis of approximately [\$6.65910] per share.

Part II, Question 17

Sections 1001 and 1012 of the Internal Revenue Code of 1986, as amended.

Part II, Question 18

A shareholder may be entitled to recognize loss on the exchange of Akoya common stock for Quanterix common stock and cash, however the loss may be subject to limitation under the Internal Revenue Code of 1986, as amended. Shareholders are urged to consult their tax advisors regarding the deductibility of a loss.

Part II, Question 19

The organizational actions occurred on July 8, 2025. The reportable tax year is 2025 for calendar-year taxpayers.